Jinshi Pharmaceutical

Founded in 2009 and based in Shanghai, China, Jinshi Pharmaceutical specializes in Contract Research, Development, and Manufacturing Organization (CRDMO) services, supporting pharmaceutical research and drug manufacturing for global clients. Jinshi Pharmaceutical, established in 2009 in Shanghai, China, operates within the pharmaceutical research and drug manufacturing sector. The company has recently pivoted to focus on its core CRDMO business model after an acquisition by Hillhouse Capital Group in September 2023. This shift is aimed at enhancing its strategic capabilities in drug discovery, laboratory testing, and process development.

The founder's specific background is not publicly detailed. Jinshi Pharmaceutical has successfully completed one notable deal, with the most recent occurring on October 24, 2025. WuXi AppTec operates as a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), offering integrated, end-to-end services in pharmaceutical research and drug manufacturing. The company's core offerings include comprehensive research and development services that assist clients in bringing new drugs from concept to market.

This encompasses drug discovery, preclinical services, clinical trial support, and commercial manufacturing. WuXi AppTec serves a diverse range of clients, including approximately 6,000 partners across over 30 countries, including multinational pharmaceutical companies and biotechnology firms. The services are designed to address critical challenges in drug development, aiming to enhance research efficiency and reduce time-to-market for innovative therapeutics. Geographically, their services extend into key markets including North America, Europe, and Asia, positioning them as a pivotal player in the global life sciences industry.

WuXi AppTec has demonstrated robust revenue growth, achieving a year-on-year revenue increase of 21. 0% in the first quarter of 2025. The company's financial model primarily revolves around B2B transactions, where it engages clients through long-term partnerships and contractual agreements for its diverse service offerings. This structure enables clients to access WuXi AppTec's extensive capabilities, which include tailored drug development and manufacturing solutions.

While specific pricing plans for individual services are not disclosed, the transactional framework typically involves fixed fees for contracted services, performance-based incentives, or milestone payments depending on the project scope and complexity. This transactional approach allows WuXi AppTec to maintain a steady revenue flow while enabling clients to achieve their research and development objectives efficiently. Following the recent acquisition by Hillhouse Capital Group, Jinshi Pharmaceutical is set to sharpen its focus on its CRDMO capabilities, specifically in drug discovery, laboratory testing, and process development. The company plans to divest non-core clinical businesses to reinvest in its globalization efforts and enhance its core capabilities.

Specific initiatives include launching new products within the CRDMO framework, targeting expansion into North America, Europe, and additional Asian markets by the end of 2025. This strategic direction is supported by the recent acquisition, which aims to streamline operations and allocate resources more effectively towards growth initiatives.